- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06247397
Efeito da terapia de alto fluxo na oxigenoterapia de longo prazo (HILOT)
Efeito da terapia de alto fluxo na oxigenoterapia de longo prazo (HILOT): um ensaio clínico randomizado, multicêntrico, baseado em registro
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.
The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Magnus Ekström, MD, PhD
- Número de telefone: +46 0455731000
- E-mail: magnus.ekstrom@med.lu.se
Locais de estudo
-
-
-
Örebro, Suécia, 70185
- Recrutamento
- Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
-
Contato:
- Josefin Sundh, MD, PhD
-
-
Blekinge County
-
Karlskrona, Blekinge County, Suécia, 37185
- Recrutamento
- Research Unit, Blekinge University of Technology
-
Contato:
- Magnus Ekström, MD, PhD
- E-mail: magnus.ekstrom@med.lu.se
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 40 years or older
- Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
- COPD or ILD as main underlying reason for LTOT
- Oxygen concentrator as stationary oxygen source in the home including night-time
- Body mass index (BMI) < 35 kg/m2
Exclusion Criteria:
- Current or previous treatment with home HFOT
- Current treatment with home mechanical ventilation
- Current treatment with home CPAP
- Hospitalized during the last 2 weeks
- Current smoking or contact with flames
- Self-reported average use of the LTOT < 15h per day (24 hours)
- PaCO2 (breathing air at rest) > 8 kPa
- Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
- Inability to participate in the study procedures (as judged by the staff)
- Not eligible for continuing LTOT due to other reason (as judged by the staff)
- Expected survival less than 3 months (as judged by the staff)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: High-flow oxygen therapy
Intervention arm |
Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time. |
|
Comparador Ativo: Low-flow oxygen therapy
Comparison arm |
Standard care with low-flow oxygen therapy in accordance with clinical routine. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to first hospitalization or death from all causes
Prazo: 1 year
|
Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data) |
1 year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to first all-cause hospitalization or all-cause death
Prazo: 1 year
|
Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data) |
1 year
|
|
Rate of hospitalizations or death from all causes
Prazo: 1 year
|
Rate of hospitalizations or death from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from all causes
Prazo: 1 year
|
Hospitalization rate from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from respiratory disease
Prazo: 1 year
|
Hospitalization rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Number of hospitalized days
Prazo: 1 year
|
Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data |
1 year
|
|
Hospitalization rate from cardiovascular disease
Prazo: 1 year
|
Hospitalization rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Number of admissions to intensive care unit (ICU)
Prazo: 1 year
|
Number of admissions to ICU assessed using nationwide registry data |
1 year
|
|
Number of days in ICU
Prazo: 1 year
|
Number of days in ICU assessed using nationwide registry data |
1 year
|
|
Mortality rate from all causes
Prazo: 1 year
|
The mortality rate from all causes assessed using nationwide registry data |
1 year
|
|
Mortality rate from respiratory disease
Prazo: 1 year
|
The mortality rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Mortality rate from cardiovascular disease
Prazo: 1 year
|
The mortality rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Time to first exacerbation
Prazo: 1 year
|
Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data |
1 year
|
|
Number of exacerbations
Prazo: 1 year
|
Number of exacerbations of all severity assessed using self-reported and registry data |
1 year
|
|
Incidence of cardiovascular disease
Prazo: 1 year
|
Incidence of cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Need for home mechanical ventilation
Prazo: 1 year
|
Need for starting home mechanical ventilation assessed using nationwide registry data |
1 year
|
|
Rate of withdrawal of long-term oxygen therapy
Prazo: 1 year
|
Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data |
1 year
|
|
Adverse events
Prazo: 3 and 12 months
|
Self-reported adverse events since study start assessed using a postal questionnaire. |
3 and 12 months
|
|
Primary care utilization
Prazo: 1 year
|
Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire. |
1 year
|
|
Health-related quality of life
Prazo: 3 and 12 months
|
Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire. |
3 and 12 months
|
|
Health status
Prazo: 3 and 12 months
|
Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire. |
3 and 12 months
|
|
Breathlessness at exertion
Prazo: 3 and 12 months
|
Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire. |
3 and 12 months
|
|
Breathlessness
Prazo: 3 and 12 months
|
Self-reported breathlessness assessed using the Dyspnea-12 questionnaire. |
3 and 12 months
|
|
Sleep quality
Prazo: 3 and 12 months
|
Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire. |
3 and 12 months
|
|
Physical activity
Prazo: 3 and 12 months
|
Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire. |
3 and 12 months
|
|
Change in health status
Prazo: 3 and 12 months
|
Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale. |
3 and 12 months
|
|
Nasal symptoms
Prazo: 3 and 12 months
|
Self-reported nasal symptoms assessed using the modified Björklund questionnaire. |
3 and 12 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient preference for continuing the treatment
Prazo: 3 and 12 months
|
Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire. |
3 and 12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Magnus Ekström, MD, PhD, Skane University Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HILOT
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .